Literature DB >> 1900059

Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.

G Corthier1, M C Muller, T D Wilkins, D Lyerly, R L'Haridon.   

Abstract

The pathogenicity of Clostridium difficile is due to the production of two toxins (toxins A and B). We prepared monoclonal antibodies against toxin A and determined whether axenic mice passively immunized with the monoclonal antibodies were protected against C. difficile disease. The mice were kept in an isolator and were given ascites fluid intravenously prior to challenge with a toxinogenic strain of C. difficile. Control mice and mice receiving ascites fluid devoid of toxin antibody died within 2 days and had high levels of toxins A and B in their feces. Mice that received ascites fluid containing high amounts of toxin A monoclonal antibodies directed against the repeating units of the toxin survived. In protected mice, toxin B levels were similar to those in dying mice, but toxin A levels were greatly reduced. These data show that passive immunity induced by monoclonal antibodies against toxin A was effective against pseudomembranous cecitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900059      PMCID: PMC258389          DOI: 10.1128/iai.59.3.1192-1195.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies.

Authors:  D M Lyerly; C J Phelps; J Toth; T D Wilkins
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 3.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

4.  Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria.

Authors:  G Corthier; F Dubos; P Raibaud
Journal:  Appl Environ Microbiol       Date:  1985-01       Impact factor: 4.792

5.  The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits.

Authors:  J M Ketley; T J Mitchell; D C Candy; D W Burdon; J Stephen
Journal:  J Med Microbiol       Date:  1987-08       Impact factor: 2.472

6.  Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice.

Authors:  S Mahe; G Corthier; F Dubos
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

7.  Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc.

Authors:  H C Krivan; G F Clark; D F Smith; T D Wilkins
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

8.  Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters.

Authors:  P H Kim; J P Iaconis; R D Rolfe
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

9.  Interrelationships between digestive proteolytic activities and production and quantitation of toxins in pseudomembranous colitis induced by Clostridium difficile in gnotobiotic mice.

Authors:  G Corthier; M C Muller; G W Elmer; F Lucas; F Dubos-Ramaré
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

10.  Effects of Clostridium difficile toxins given intragastrically to animals.

Authors:  D M Lyerly; K E Saum; D K MacDonald; T D Wilkins
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

View more
  42 in total

Review 1.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

2.  Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A.

Authors:  C Pothoulakis; R J Gilbert; C Cladaras; I Castagliuolo; G Semenza; Y Hitti; J S Montcrief; J Linevsky; C P Kelly; S Nikulasson; H P Desai; T D Wilkins; J T LaMont
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 3.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 4.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.

Authors:  S W Pawlowski; G Calabrese; G L Kolling; J Platts-Mills; R Freire; C AlcantaraWarren; B Liu; R B Sartor; R L Guerrant
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

6.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

7.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

8.  Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.

Authors:  J F Torres; D M Lyerly; J E Hill; T P Monath
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

9.  Heterogeneity of Clostridium difficile isolates from infants.

Authors:  A Collignon; L Ticchi; C Depitre; J Gaudelus; M Delmée; G Corthier
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

10.  Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin.

Authors:  Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.